BREAKING NEWS: Advaxis Reports Preliminary Safety and Survival Data from a Phase 2 Trial in Recurrent/Refractory Cervical Cancer
Click below to hear live audio interview with Thomas Moore, CEO. PRINCETON, N.J., Jan. 25 — Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, reported preliminary...
recent news
Written on Jan 26, 2012
Written on Jan 25, 2012
Written on Jan 24, 2012
Written on Jan 23, 2012
Written on Jan 23, 2012
Written on Jan 23, 2012
S.E.A. Medical Secures $3 Million in Series B Fina...
SANTA CLARA, Calif.–S.E.A. Medical Systems Inc., a healthtech company focused on safety and management of IV medicine, today announced that it closed a $3 million Series B investment with Chicago-based venture capital firm JK&B Capital, which specializes in...
Provectus Receives Guidance From FDA On Pathway to...
KNOXVILLE, Tenn.–(BUSINESS WIRE)–Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, has received guidance from the U.S. Food and Drug Administration (“FDA”)...
This Week In Diagnostics
Clinical trial initiated for Trisomy 21 test
Aria Diagnostics (formerly Tandem Diagnostics) says that it is initiating a multicenter clinical trial that compares its non-invasive prenatal test with the standard first-trimester screening test (serum screening and nuchal...
Miracor Aims to Cure More Than 350K Broken Hearts ...
Miracor Medical Systems is a privately held medical technology company based in Vienna, Austria and is aiming to help patients who have experienced cardiac surgery or suffer from acute coronary syndrome (ACS) improve their quality of life.
Their main technology is...
Biocept, Inc. Making Advances in Circulating Tumor...
Biocept Inc. is a privately held laboratory testing company based in San Diego, Calif. focused on detection and analysis of circulating tumor cells (CTCs) in cancer patients.
Their most recent project was documented in a paper published in the December 2011 issue of...
Microvisk Limited Uses Same Technology as iPhone, ...
Microvisk Limited is a UK-based medical technology company focused on developing medical testing devices based on micro electro medical sensors (MEMS) for the international healthcare market. The company is owned by private and venture capital investors including...
popular news
- Non-Invasive Glucose Monitor Cleared in Europe (14)
- InSound Medical's Lyric: A Long Time Coming (11)
- New Study Highlights Promising Gene-Based Predictor of Prostate Cancer Risk (8)
- [Quick Take] Interview with Jeff Rencher, President of Sales & Marketing at Opticon Medical (6)
- Revolution Health Takes on WebMD with User-Centric Focus (5)
- Blue Shield of California Sees the 308-nanometer Light (5)
- srebrenik shalom: we invested a lot of money in ADXS from the very begining an...
- Alan S. Frankel: This conference call was excellent and I hope to follow Adva...
- Copd untreated: What's COPD? COPD = continual Obstructive lung. Do you kn...
- nicolette richards: I am 19 years old and I have trisomy 20 mosaicism and I was ...
- eric: brett, thanks for this interview i just became a sharehold...
- Jonathan Stuart: Pre-IPO funds are also run by MidasLP.com, GSV and several o...
recent from News
BREAKING NEWS: Advaxis Reports Preliminary Safety and Survival Data from a Phase 2 Trial in Recurrent/Refractory Cervical Cancer
Click below to hear live audio interview with Thomas Moore, CEO.
PRINCETON, N.J., Jan. 25 — Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, reported preliminary...
Click below to hear live audio interview with Thomas Moore, CEO.
PRINCETON, N.J., Jan. 25 — Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, reported preliminary...
recent from Research
ADVENTRX Pharmaceuticals Takes the Next Step In Approval of ANX-530
ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX), with its leading innovations in anti-cancer drug development has just announced that they’ve been successful in sending their ANX-530 (Exelbine™) New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) with a Prescription Drug...
ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX), with its leading innovations in anti-cancer drug development has just announced that they’ve been successful in sending their ANX-530 (Exelbine™) New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) with a Prescription Drug...
recent from Profiles
Navigating the Perilous Road: A Special Panel On Regulatory and Reimbursement Issues
The US market represents huge profit potential for an innovative company, but not if unexpected FDA issues impede the launch, or reimbursement issues and adverse patent actions interfere with the success of the product.
Recent studies have indicated that the time to gain approval is dramatically different...
The US market represents huge profit potential for an innovative company, but not if unexpected FDA issues impede the launch, or reimbursement issues and adverse patent actions interfere with the success of the product.
Recent studies have indicated that the time to gain approval is dramatically different...
recent from Video
June 23-24 OneMedForum New York
OneMedPlace Trans-Atlantic Conference on June 23rd-24th is a gathering of fast growing, emerging healthcare and life science companies in Europe and North America.
Its sixth OneMedForum, and second in New York, OneMedPlace will focus on critical success factors for building companies on both sides of the...
